RxDoctor Payments Data

Margaret Pfeiffer, MD

Ophthalmic Plastic and Reconstructive Surgery · Dallas, TXNPI 1679816862

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,278 of the $4,278 with a category attached, or 76.6%. Amgen accounts for 77.4% of it on its own, with 8 other manufacturers making up the rest.

$4,278in general payments, 2019–2025

Across 64 payments — averaging $66.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • Merz Pharmaceuticals, LLC$230
  • Kerecis Limited$171
  • Eyevance Pharmaceuticals LLC$163
  • Biotissue Holdings Inc.$153
  • Bausch & Lomb Americas Inc.$140
  • plus $108 from 3 others

What the payments were for

  • Consulting fees$1,00023%
  • Food & beverage$3,27877%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,278 in reported general payments places this provider in the 70th percentile of 36 ophthalmic plastic and reconstructive surgery providers in Texas.

See all ophthalmic plastic and reconstructive surgery providers in Texas

Medicare billing

Part B allowed, 2024
$227,898
Medicare patients
390
Services billed
7,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha444$4,926
Prednisolone Acetate27$1,510
ErythromycinErythromycin Base76$892
Tramadol Hcl186$281
Ofloxacin24$252
Doxycycline Hyclate14$169
Methylprednisolone13$93

Paid to pharmacies, not to this prescriber.

Other ophthalmic plastic and reconstructive surgery in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →